论文部分内容阅读
紫杉醇(Paclitaxel,Taxol;布迈·施贵宝)已被食品和药品管理局批准用于治疗那些对其他化学疗法已失去反应或仍在继续发展的卵巢癌。紫杉醇是紫杉烷这类新骨架化合物中的第一个,它能干扰细胞分裂、阻止癌细胞增殖。该药已被广泛宣传。由于必须从太平洋紫杉这一珍稀树木的树皮中提取该药,因此该公司计划开发其他资源并在1995年底以前停止使用紫杉树皮。紫杉醇将免费提供给未保险的病人及那
Paclitaxel (Taxol; Bumaisi Squibb) has been approved by the Food and Drug Administration for the treatment of ovarian cancers that have become inactive or continue to develop on other chemotherapies. Paclitaxel, the first of its kind of new scaffold compounds, can interfere with cell division and prevent cancer cells from proliferating. The drug has been widely publicized. As the medicine must be extracted from the bark of this rare tree of Pacific yew, the company plans to develop other resources and stop using the yew tree bark by the end of 1995. Paclitaxel will be offered free to uninsured patients and that